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A NEW ALGORITHM FOR THE MANAGEMENT OF DERMATOFIBROSARCOMA
PROTUBERANS.
Carolyn Goldberg and Deepak Narayan. Division of Plastic Surgery, Department of
Surgery, Yale University School of Medicine, New Haven CT.
The purpose of this project was to design an algorithm for the management of
Dermatofibrosarcom Protuberans (DFSP.) The National Cancer Center Network
guidelines suggest immediate reconstruction in most cases after DFSP resection. We
believe this algorithm is inadequate. Due to the infiltrating nature of DFSP, tumor
margins are often positive after resection. Immediate reconstruction in the context of
residual tumor is problematic because of the risk for spreading microscopic disease and
the potential to compromise reconstructive options. At our institution we examined the
prevalence of positive margins on permanent pathology after immediate closure
following surgical resection of DFSP. Forty-one patients were identified; 25 had
received treatment with surgical excision and 16 with Mohs surgery. Of the 25 patients
that were treated with surgical excision, 20 underwent immediate closure and 5
underwent delayed closure after tumor resection. Eight out of 19 (40%) of patients who
underwent immediate closure were found to have positive margins on permanent
pathology. Given these findings, we propose a treatment algorithm focused on more
conservative surgical management of DFSP in which negative margins are established
before closure. Mohs surgery, which allows for immediate identification of pathology,
plays a central role.
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INTRODUCTION
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally invasive soft tissue sarcoma
with a propensity for extensive subclinical involvement. Originating in the dermal layer
of skin, microscopic tendrils of tumor may extend far beyond the margin of clinically
evident tumor. While painless and often indolent appearing, the tumor can grow quite
large before receiving clinical attention. Local invasion can include subcutaneous tissue,
muscle, fascia and bone. The local recurrence rate is high, in some studies upwards of
60%, likely reflecting a failure to remove occult extensions of tumor.1 Fortunately,
distant metastasis is rare (between 1 and 4%) and complete removal is considered
curative.2
The cell of origin for DFSP is controversial. Several authors theorize that DFSP
arises from fibroblasts, as tumor cell features that are consistent with modified fibroblasts
have been observed on electron microscopy.3 In addition, like fibroblasts, DFSP cells
stain with vimentin and contain active endoplasmic reticulum that readily synthesize
collagen.4 However, several studies in tissue culture indicate that tumor cells may be
histiocytes that have acquired fibroblastic elements. The growth pattern of DFSP
resembles that of fibroblasts in the body, which serve to support tissue through formation
of a lattice network around cells. DFSP cells mimic the fibroblast infiltrative growth
pattern with pseudopod like extensions from a central mass that penetrate fat and adjacent
tissue over time.3 It may be that this similarity to the fibroblast growth pattern explains
the low rate of blood borne metastasis, as fibroblasts tend to remain enmeshed in the area
they stabilize.5 Histologically, DFSP is characterized by a fibroblastic proliferation of
tumor cells arranged about a central hub in a storiform pattern.2 (Figure 1)
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Figure 1. Microscopic appearance of DFSP

Ninety percent of DFSP tumor cells exhibit a chromosomal translocation of genes
COL1A9 and PDGFβ (t17;22,) which encode the alpha chain of type I collagen and the
beta chain of platelet-derived growth factors, respectively.6 The fusion protein produced
by this translocation causes continuous stimulation of the PDGF protein tyrosine kinase,
resulting in increased production of PDGF and abnormal cellular proliferation.7
Fibrosarcomatous-DFSP is a more aggressive variant of DFSP and likely represents
dedifferation. The increased cellularity and mitotic activity observed on histology for
these tumors are indistinguishable from the cytologic and architectural pattern of a high
grade fibrosarcoma, and this variant is associated with a higher rate of recurrence and
metastasis.6,8,9
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The development of DFSP may be linked to traumatic wounds, scarring, and
viruses. In a retrospective analysis by Yu et al., 24% of patients recalled an antecedent
trauma at the site of tumor development.10 Green et al. describe a 69-year old who
presented with a DFSP located at a smallpox vaccination site.11 At least six other
accounts of DFSP exist in which the tumor developed in a site of prior immunization
inoculation.11 Persistent inflammation is thought to account in part for the association of
scars with an increased risk of malignancy.10
Historically, surgical excision has been the treatment of choice for the resection of
DFSP. However, the ideal width of margins remains undefined. Parker et al. mapped the
subclinical tumor extension in 20 patients with Mohs surgery and measured the margins
required to completely clear the tumor. A 2.5 cm margin through the deep fascia was
shown to clear all tumor cells completely, and the tumors measuring less than 2 cm were
completely cleared with a 1.5cm margin.12 However, other studies have documented
tumor projections that extend anywhere from 3 to 10 cm beyond the tumor center leading
to recommendations for margins of up to 5cm.4,13 A review of the literature by Gloster et
al. found a trend of improving recurrence rates with increasingly wider resection margins.
The recurrence rate decreased from an average of 43% to 18% in series with wider
margins (defined as greater than or equal to 2 cm) compared to undefined or more
conservative margins.2 Even among studies where resection margins were 5 cm, the
recurrence rate reached 23%.14 Most authors currently suggest a margin of 2 to 3 cm
with a three dimensional resection including skin, subcutaneous tissue, and the
underlying investing fascia.8
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Several authors have suggested that traditional surgical excision, which removes
tissue in a concentric ring based on the macroscopic extent of the tumor, is not well
suited for removal of DFSP. This surgical approach is predisposed to remove too much
healthy tissue without eradicating the extensive, asymmetric projections of tumor cells.13
In the last several decades, Mohs surgery has emerged as a promising treatment option
that may achieve superior results to surgical excision.15 Mohs surgery provides a method
of eradicating tumor that rests on intraoperative evaluation of tumor margins. The tumor
is resected in a stepwise fashion with tissue removal that is based on the presence of
tumor cells. In addition to conserving tissue, the pathologic techniques used in Mohs
surgery have been shown to provide an excellent rate of cure with very few documented
recurrences.
After resection of DFSP, the National Comprehensive Cancer Network (NCCN)
guidelines recommend immediate reconstruction in most cases, but state that “it is
preferable to delay deep undermining or flap reconstruction until negative surgical
margins are assessed.”16 These recommendations for treatment of DFSP are potentially
problematic because of the emphasis on clinical judgment for determining whether to
perform immediate or delayed reconstruction. It is often difficult to predict the extension
of the tumor, because of the eccentric pattern of invasion characteristic of DFSP that
mimics normal tissue.17 Immediate reconstruction can compromise options for
subsequent surgery if positive margins found on permanent pathology necessitate further
excision. In addition, immediate reconstruction in the context of residual tumor may
pose a risk for the spread of microscopic disease. For these reasons, we believe the
current guidelines for the management of DFSP are inadequate.
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STATEMENT OF PURPOSE
The purpose of our study is to design an algorithm for the management of DFSP focused
on establishment of negative margins before closure.

METHODS
Patients were identified through the surgical pathology and dermatopathology laboratory
database and stratified by surgical treatment type: surgical excision or Mohs surgery.
Data was collected retrospectively and entered into de-identified research records.
Twenty-one patients were identified in the Yale surgical pathology database as
having received surgical treatment for DFSP from 1990 to 2009. We included cases in
which pathology of a biopsy of the lesion was consistent with DFSP. All patients who
underwent surgery for DFSP were included. Patients were defined as having primary
disease if they had never received previous treatment for DFSP, and recurrent disease if
tumors arose at the site of previous resection. Patients with primary DFSP presented at
our institution either for initial treatment or after previous inadequate surgery to undergo
re-excision. Hospital and clinic outpatient charts were obtained and the following
information was collected: age at onset, sex, disease state (primary presentation versus
recurrence), tumor site, type of closure, size of margin, need for local tissue flaps and
skin grafts in closure, status of margins on permanent pathology, and duration of follow
up. We recorded the margin noted in the initial operative report as well as margins taken
during subsequent resections. Margin size was missing for two patients. In addition, we
recorded whether patients experienced disease recurrence (recurrent tumor after negive
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pathology following resection) or extension of disease (recurrent tumor after incomplete
resection.)
Twenty patients were identified by the Yale dermatopathology laboratory database
as having been treated at this institution for DFSP from 1990, when the database was
created, to 2009. These patients were stratified by the type of surgical treatment they
received. Four patients were treated with surgical excision and 16 patients were treated
with Mohs surgery. The patients who received surgical excision were grouped with the
patients from the Yale surgery pathology database and evaluated for the same factors
listed above. Information from the medical charts of the patients who received Mohs
surgery was collected on tumor site, type of closure performed, number of stages and
histologic sections during surgery, size of lesion, size of the postoperative defect (defined
as the wound dimensions recorded in the operative report immediately prior to closure)
and duration of follow up. Tumor size or size of postoperative defect was missing for
two patients.
In addition to the above parameters, we wanted to compare the margin size for
Mohs surgery with the margin size used during surgical excision to determine whether
Mohs surgery conserved more normal tissue than surgical excision. Because data on
excisional margins was not available for Mohs surgery patients, we calculated the
margins in the following manner: the larger measurement of the preoperative defect size
was subtracted from the larger measurement of the postoperative tumor size to obtain a
total margin. This margin was divided in half based on the assumption that the margin
was applied circumferentially around the lesion to yield the actual margin. The smaller
measurement of the preoperative tumor size was also subtracted from the smaller
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measurement of the postoperative defect size and divided in half. The two values were
averaged to arrive at the excisional margin for each patient.
This study was approved by the Yale University Human Investigation Committee
(HIC#0803003577).

RESULTS
Forty-one patients were treated for DFSP by surgical excision, Mohs surgery, or a
combined approach at our institution from 1990-2009. The distribution of lesions is
summarized in Figure 1. Overall, the trunk was the most common site for DFSP,
followed by the head and neck. No patients had distant metastasis at the time of
diagnosis. One patient presented with extension of disease after incomplete resection in
the surgical excision group. No patients experienced recurrence (presentation of disease
after negative surgical margins) in either the surgical excision or the Mohs surgery group.
The average duration of follow up was 107.9 months for all patients.

Figure 2. Distribution of Lesions
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Surgical Excision Group (Table 1)
Twenty-five patients underwent surgical treatment for removal of DFSP between
1990 and 2009 by 20 surgeons in the Division of Plastic Surgery, Department of Surgery,
and Section of Dermatologic Surgery and Cutaneous Oncology in the Department of
Dermatology. Excluding two patients for whom the state of disease was not reported
78.3% of patients presented with primary disease and 34.8% presented with recurrent
disease. The age range was 12 to 84 years with a mean age of 46.1 years. Sixty-eight
percent of patients were female and 32% were male.
Sixty-four percent of the lesions were found on the trunk, 28% were found on the
head and neck, and the remaining lesions were found on the extremities. More
specifically, there were five lesions on the back, four on the shoulder, three on the chest,
three on the abdomen, and one on the breast. Two patients had lesions on their lower
extremities. In the head and neck region, there were two patients with scalp lesions, two
patients with lesions on or around the temple, one patient with a lesion over the parotid
gland, and one patient with a lesion on the posterior neck. One DFSP lesion was found
on the eyelid.
The average margin size for patients after initial surgical excision was 2.33 cm.
The narrowest margin taken was .75 cm (for the patient with DFSP of the eyelid) and the
widest margin was 4.5 cm. However, the average surgical margin including all
subsequent surgical resections after permanent pathology was 2.79 cm, with a maximum
width of 6 cm. The median margin size was 2.5 cm after initial surgical resection and 3
cm after including cumulative surgical resections. Five patients underwent delayed
closure and 20 patients underwent immediate closure after resection. Twelve patients

13

(48%) were found to have positive margins after initial resection. The duration of follow
up ranged from 27 to 105.5 months, with an average of 105.5 months (8.75 years.)
Delayed Closure (Figure 1)
Five patients (20.8%) underwent delayed closure of the wound with planned reoperation and closure pending the results of permanent pathology. Two of these patients
presented to our institution with recurrence, and one patient presented from an outside
hospital for further resection after positive margins were found on initial resection.
Allograft was placed on the wound as a temporary dressing for all five of these patients.
The average time between the first and second surgery was 8.2 days, with a minimum of
three days and a maximum of 13 days. Four of the five patients were found to have
positive permanent pathology necessitating further resection. All but one patient was
cleared histologically after a second resection.
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Figure 3. Images of a patient treated with delayed reconstruction after resection of DFSP
of the left chest wall. A. Gross appearance of lesion. B. Specimen. C. A 30 by 20 cm
defect was present after tumor resection. D. Allograft was used to temporarily close the
defect. E. The results of permanent pathology showed tumor extension at the 7-8 o’clock
margin, with skeletal muscle negative for malignancy. The patient underwent further
resection 19 day later, with intraoperative frozen sections of the new margin found to be
negative. Closure was performed with Gore-Tex mesh and bilateral external oblique
myocutaneous flaps. No malignancy was found on permanent pathology after reexcision. E. Photograph from follow up appointment at clinic.
A.
B.
2

C.

D.

E.

F.
F.
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Immediate Closure
Twenty patients (80%) underwent immediate closure after surgical resection. Six
of the patients who were treated with immediate closure had presented to our institution
with recurrent disease. Eleven patients who received immediate closure required local
flaps for reconstruction. One patient underwent immediate reconstruction with a radial
forearm free flap.
Eight of the 20 patients (40%) who received immediate closure were found to have
positive margins on permanent pathology. Three of these patients had undergone
reconstruction with local flaps.
One patient received combined treatment with surgical resection followed by Mohs
surgery. This was a 33 year-old woman who had previously been treated for DFSP of the
forehead and upper eyelid at an outside hospital. She presented to the plastic and
reconstructive surgery clinic at our institution with recurrent disease. She was treated
with resection of tumor to the periosteum of bone. Intraoperatively, frozen sections
showed negative margins. After surgery she received immediate reconstruction with a
split-thickness skin graft. Permanent margins extending into the upper eyelid were found
to be positive. She was referred for Mohs surgery where the resection was completed.
One patient in the surgical excision group presented with extension of disease after
incomplete surgical excision. This was a 48 year-old female who received immediate
reconstruction after resection of a large DFSP of the scalp and was found to have positive
margins on permanent pathology. The patient was referred for radiation therapy, but
elected to pursue observation of the lesion only. Two years later, the patient presented
with nodules at the edge of the split thickness skin graft found to be DFSP. She
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underwent further resection, this time with reconstruction of the defect with a
fasciocutaneous flap from the posterior cervical muscles. On permanent pathology, the
tumor approached within 1 mm at the deep margins. The patient elected to pursue
radiation therapy, and has had no recurrences in the four years following treatment.
Table 1. Permanent pathology results after surgical excision
Number of Patients
(Percent)

Positive Margins
(Percent)

Negative Margins
(Percent)

Immediate Closure

19 (79.2%)

7 (36.8%)

12 (63.2%)

Delayed Closure

5 (20.8%)

4 (80%)

2 (20%)

Mohs Surgery Group (Table 2)
Mohs surgery was performed on 16 patients by three dermatologists in the Section
of Dermatologic Surgery and Cutaneous Oncology in the Department of Dermatology.
Like the surgical excision group, most lesions (56.3%) were found on the trunk. A
greater percentage of lesions were found on the extremities than for surgical excision
(31.3 vs. 8.0%), and fewer lesions were found on the head and neck (12.5 vs. 28.0%).
More specifically, there were three lesions on the back, three on the shoulder, two on the
abdomen, one on the chest, and one on the hip. Two patients had lesions on the clavicle
and scalp at the hairline. Of the five patients with lesions on the extremities, 2 patients
had lesions on the hand, two on the calf or lower leg, and one on the dorsum of the foot.
Thirteen lesions (81.3%) approached initially with Mohs surgery were cleared
histologically after five stages of Mohs surgery. Three patients were referred for surgical
excision because of failure to achieve clear margins with local anesthesia at the time of
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Mohs surgery. These patients continued to have one histologic section positive after four
stages of surgery and out of 9, 12, and 14 total histologic sections.
Most patients required several staged Mohs excisions to achieve complete tumor
clearance. Thirty-one percent of lesions were excised in a single procedure, 12.5% were
excised after two stages, 18.8% after three stages, 12.5% after four stages, and 6.3% after
five stages. At each stage of resection, multiple histologic sections were required to
analyze the entire peripheral margin. Excluding the three patients referred for further
surgical excision, the average number of histologic sections taken was 8.6. The
minimum number of sections was two and the maximum was 19.
Of the patients with lesions cleared by Mohs surgery, two patients (15.4%) were
left to heal by secondary intention, 10 (76.9% ) of the patients underwent complex linear
closure, and one patient was referred to a plastic surgeon for wound closure. The average
margin taken was 1.36 cm, with a median margin width of 1.17 cm. The maximum
margin taken was 2.55 and the minimum margin was 0.74 cm.
No patient in the Mohs excision group experienced recurrence over a follow-up
period ranging from 10.5 to 200.5 months, with an average duration of follow-up of 112
months.
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Table 2. Patient Characteristics and Results of Mohs Surgery
Patient

Location

Stages Required
for Clearance

Total
Sections

Closure Type

Size of Lesion
(cm)

1

L lateral calf

1

4

Secondary
intention

2

L dorsal hand

3

5

CLC

3

L shoulder

3

23

Delayed*

4

L abdomen

2

14

CLC

7 x 1 scar

5

L deltoid

1

2

CLC

1 x 1.5

6

L hip

1

4

CLC

0.3 x 2.5

7

L dorsal hand

5

19

CLC, small area
left to granulate

4.8 x 1.7

8

R lower leg

4

13

Secondary
intention

9

R inf back

2

6

CLC

3 x 2.4

10

L flank

1

4

CLC

7.6 x 0.3

11

R ant sup
Shoulder

4

12

CLC

0.9 x 0.7

12

R upper back

3

4

CLC

1.2 x 1.3

13

R abdomen

1

2

CLC

1.3 x 1.2

14

R clavicular
area

4**

9

CLC*

3 x 1.5

15

Ant. R scalp at
hairline

4**

14

Delayed*

2x5

16

Foot

4**

12

Delayed*

1x3

CLC: Complex linear closure
**negative margins not achieved with Mohs surgery.
*patients referred to plastic surgeon for further surgical resection and/ or closure

1.9 x 2
0.7 x 0.4
Not reported

2x1
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DISCUSSION
As mentioned above, the National Comprehensive Cancer Network (NCCN)
guidelines for management of DFSP recommend immediate closure in most cases,
although “it is preferable to delay reconstruction involving extensive undermining or
flaps until negative surgical margins are assessed and certified pathologically clear.”16
Given the important prognostic relevance of establishing negative margins, we believe
that reconstruction after tumor resection should be dependent on definitive clearance of
the tumor. In light of the difficulty in judging the extent of DFSP, and the potential
complications of reconstruction after positive margins are found, we feel that the
treatment guidelines should be more conservative. Although multiple algorithms for the
treatment of DFSP exist,10,18 few incorporate closure guidelines into the
recommendations. Here we present a new algorithm for surgical management of patients
diagnosed with DFSP focused on the establishment of negative margins before closure
(Figure 4.) Mohs surgery, which allows for immediate identification of pathology, plays
a central role. Following a description of the algorithm, we will further discuss
conservative treatment modalities such as Mohs surgery and surgical excision with
delayed closure. Finally, we review reconstructive options after resection, and further
therapy for metastatic DFSP and unresectable DFSP.
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Figure 4.

The extent of DFSP is difficult to determine intraoperatively with traditional surgical
excision, leading to a high rate of positive microscopic margins. In our analysis, nearly
half of all patients (48%) had positive margins after initial tumor resection, despite wide
surgical margins (median initial resection margin was 2.5 cm) that fell well within the
accepted wide excision widths in the literature.8 Rearrangement of tissue during closure
may disseminate residual tumor cells, making re-resection of the positive margin
inadequate to remove all disease. Resection with delayed closure ensures that further
margins will be removed if permanent pathology is positive without tissue rearrangement
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that may distort the tumor cell orientation. Therefore each step of the algorithm centers
on establishing negative margins before closure.
Given the many advantages of Mohs surgery and the high safety profile that has
been found, we believe that Mohs surgery should be the first line treatment when
feasible. After clinical assessment of the tumor, all patients who are candidates for Mohs
surgery should undergo this method of treatment where margins can be visualized in real
time. Ultimately the decision of whether or not a patient will undergo Mohs surgery will
be made on a case by case basis depending on the patient, location of the tumor with
respect to the cutaneous tissue, and the experience of available clinicians. If Mohs
surgery fails to achieve complete resection because the lesion extends into deep structures
or the patient cannot tolerate further surgery under local anesthesia, the patient may be
referred for surgical excision.
Patients for whom Mohs surgery is not feasible should undergo surgical resection
of the tumor followed by temporary wound closure until the results of permanent
pathology are known. As mentioned above, this will prevent rearrangement before full
eradication of tumor cells. If pathology is found to be negative, reconstruction can
proceed safely and without the risk of compromising any reconstructive options.
If positive margins are found on permanent pathology after resection, the lesion
should be re-evaluated for Mohs surgery. In many cases, Mohs surgery can be applied to
regions known to exhibit positive margins in order to minimize tissue loss. If Mohs
surgery is not feasible, additional surgical excision should be performed. If there is a
concern for positive margins, the patient should once again be left with a temporary
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dressing with closure deferred until definitive negative pathology returns. This process
should be repeated until permanent pathology demonstrates an absence of tumor cells.
Recurrent DFSP, lesions that continue to exhibit positive margins after multiple
resections, and patients for whom complete tumor resection would cause a mutilating
deformity require special considerations. These patients may benefit from radiation
therapy in the postoperative or preoperative period. In addition, patients with the
fibrosarcomatous high-grade variant of DFSP may require a more intensive treatment
approach.20
After permanent pathology demonstrates an absence of tumor cells, reconstruction
can be safely performed. When margins are known to be negative flap coverage is a safe
and cosmetically superior method of closure. We believe that this algorithm will lead to
systematic and successful extirpation of DFSP with a drastic reduction in recurrence rates
as well as decreased tissue defects leading to improved cosmetic results.
Eighty percent of patients at our institution were treated with immediate closure
following surgical excision of DFSP, and fifty percent of all patients underwent
immediate closure with flaps. A significant number of patients (40%) who underwent
immediate closure were found to have positive margins on permanent pathology. This
necessitated re-opening of the previous closure for further excision of tumor cells and
subsequent reconstruction of the defect. Three patients found to have positive margins
had undergone more extensive immediate reconstruction with flaps. These findings are
consistent with the unpredictable extent of DFSP; even patients with wide excisions have
been found to have a high rate of positive margins.9,17 This is likely due to the infiltrating
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nature of DFSP and projecting tumor tendrils that mimic normal tissue and are therefore
difficult to detect macroscopically.9
As mentioned above, immediate reconstruction after excision of a DFSP can be
problematic if margins are found to be positive on permanent pathology. The first
closure may limit subsequent reconstructive options, particularly in areas with large
defects or around the head and neck, where reconstructive options are already limited.
Immediate reconstruction in the context of residual tumor also poses risks for the spread
of tumor cells. Undermining tissue for flap reconstruction, or simply tissue reapproximation, has the potential to open new tissue planes for tumor implantation.
Dubay et al. reported their experience with a patient who had undergone immediate
closure at an outside institution with bilateral rotation flaps and was found to have
positive margins on permanent pathology. The initial tumor was described as less than 1
cm, and when flaps were re-resected, the tumor was found to extend through the entire
undermined tissue plane beneath flaps, with no tumor noted in the overlying superficial
adipose or dermal tissue.19 This observation highlights the risk of infiltration of residual
tumor cells into the plane of dissected tissue. It is also possible that the rearrangement of
tissue during closure may disseminate tumor cells, making re-resection of the positive
margin inadequate to remove all disease.
Achieving clear margins after the first resection of the tumor has been found to be
critical to the prognosis of DFSP. In a review of the current management of DFSP,
McArthur et al. highlighted the importance of achieving local control by adequate initial
resection because locally recurrent and neglected lesions have a propensity for deep
fascial, muscular, and bone invasion, as well as an increased likelihood of recurrence
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leading to metastasis.20 Arnaud et al. reviewed the outcomes of 114 patients who had
undergone surgical treatment for DFSP with a mean follow-up time of 61 months.21
Interestingly, the authors found that the rate of recurrence was not related to the size of
the tumor. Two out of 41 patients treated with wide resection for a recurrent tumor
developed further local disease and died of metastatic fibrosarcoma, compared with none
of the 60 patients treated with wide initial resection. The authors concluded that accurate
initial resection of the tumor is the most important prognostic factor for decreased
recurrence and metastasis. Resection with delayed closure ensures that further margins
will be removed if permanent pathology is positive without tissue rearrangement that may
distort the tumor cell orientation.
Bowne et al. confirmed the importance of initial accurate resection in a large
retrospective analysis of patients treated for DFSP at the Memorial Sloan-Kettering
Cancer Center.9 The authors analyzed clinicopathologic factors for disease-free survival
in 159 patients at their institution. Patients were separated based on whether they
exhibited the classic form of DFSP or the fibrosarcomatous "high grade" variant. As
mentioned earlier, the fibrosarcomatous variant (FS-DFSP) is a much more aggressive
tumor and carries a worse prognosis. Like Arnaud et al., the authors found that tumor
size, site, and depth did not correlate with increased recurrence. However, positive or
very close (less than 1 mm) to positive microscopic margins was a poor prognostic factor.
Classic DFSP resected with negative microscopic margins was found to have a
recurrence rate of 7%, while classic DFSP resected with positive microscopic margins
was found to have a recurrence rate of 27% at five years. The more aggressive
fibrosarcoma variant of DFSP was found to have a recurrence rate of 28% and 100% at
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five years with negative and positive margins, respectively.9 The authors concluded that
incomplete resection of tumors cells was correlated with a high disease relapse rate.
A 2003 study by Khatri et al. further underscored the importance of adequate initial
excision of DFSP. In this study, recurrent lesions were found to have a propensity for
deep fascial, muscular, and bone invasion when compared to primary lesions.8 In
addition, there is a risk of de-differentiation of DFSP to the FS-DFSP variant, which as
noted earlier is associated with a further increased recurrence rate and rate of metastasis.8
Other studies have shown that metastases are usually preceded by multiple local
recurrences after inadequate initial resection.2
No patients in our study experienced recurrence after treatment with surgical
excision or Mohs surgery over an average follow-up period of 8.9 years. This recurrence
rate is significantly lower than the 18%-43% averages found in a literature review.2 One
patient in our study presented with extension of disease after incomplete surgical
excision. As mentioned above, this was a 48 year-old female with a 10 by 11 cm DFSP
of the scalp. The tumor was initially excised with three centimeter margins and
immediate closure was performed after resection with a split-thickness skin graft. After
permanent pathology showed positive deep margins, the patient was referred for radiation
therapy. She elected to pursue observation of the lesion only. Two years later, the
patient presented with nodules at the edge of the split thickness skin graft found to be
recurrent DFSP. She underwent further resection, this time with reconstruction of the
defect with a fasciocutaneous flap from the posterior cervical muscles. On permanent
pathology, the tumor approached within 1 mm at the deep margins. The patient elected
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to pursue radiation therapy, and has experienced no further extension of disease in the 4
years following treatment.

Mohs Surgery

Mohs surgery provides a method of eradicating tumor that rests on intraoperative
evaluation of tumor margins, without the need for deferral of closure. During Mohs
surgery, frozen sections are taken in real time while the patient is awake. This offers
several advantages over surgical excision, not the least of which is that the patient is not
exposed to the inherent risks of prolonged general anesthesia. The tumor is resected in a
stepwise fashion with the understanding that further sections will be removed but that
tissue removal will be based on the presence of tumor cells. The processing for Mohs
surgery involves drawing a map of the specimen and dividing this into smaller segments
which can be frozen and color-coded with dyes in order to create a a comprehensive
anatomic map that can be visualized histologically. Sections are cut along the periphery
on a continuous plane from the surface at the edge to the deepest portion of the edge,
allowing complete visualization of the margins.22 For this reason, smaller surgical
margins are possible with maximal preservation of unaffected healthy tissue. In our
study, the median margin taken during Mohs surgery was over 1cm less than the median
margin used in surgical excision (1.17 compared to 2.5 cm). When surgical margin was
calculated including all subsequent resections, the difference between median margin size
increased (1.17 compared to 3.00 cm). This finding is not surprising given the technique
used in Mohs surgery. For areas of the body where generous excisional margins are not
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practical, such as the face or extremities, this conservation of normal tissue represents a
significant reconstructive advantage. In addition, Mohs surgery provides real-time
definitive information about margins without requiring subsequent procedures and
delayed closure.
Mohs surgery frozen sections must be differentiated from intraoperative frozen
sections that may be processed during surgical excision. The role of intraoperative frozen
sections for determining the status of margins in real time remains undefined.
Intraoperative frozen sections are not routinely processed and analyzed with the same
meticulous mapping technique as in Mohs surgery and therefore do not carry the same
reliability. In comparison to Mohs frozen sections, intraoperative frozen sections are
processed using a standard vertical step sectioning which permits examination of a
random number of individual sections from the excised specimen.1 Therefore the
specimen is not comprehensively viewed by the pathologist, and a margin may be called
falsely negative if the sections viewed by the pathologist do not contain tumor cells.
Stojadinovic et al. compared intraoperative frozen sections to permanent pathology for 20
patients who were treated for DFSP of the head and neck at Memorial Sloan-Kettering
Cancer Center between 1964 and 1999. The authors found that intraoperative frozen
sections carried a sensitivity of 43% and a false negative rate of 57%, and concluded that
intraoperative frozen sections do not assess resection margins accurately.23 In our case
series, two patients were found to have positive margins on permanent pathology despite
negative intraoperative frozen sections. While intraoperative frozen sections may be used
to guide resection, they are not reliable in assessing DFSP margins and should be used
with caution when determining whether reconstruction can safely proceed.
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While Mohs surgery provides a more accurate analysis of margin status than
routine intraoperative frozen sections, the Mohs technique has several shortcomings
when compared to permanent pathology processing. Several authors have described the
difficulty delineating tumor borders during Mohs surgery at the periphery of frozen
specimens where malignant cells become sparse and resemble normal fibroblasts.24
These confounding cells are not found on paraffin sections. In cases where the extent of
the tumor is difficult to judge, some authors advocate taking a biopsy of an analogous
area to serve as a control in order to differentiate the normal distribution of fibroblasts
from tumor cells. In addition, frozen sections in Mohs surgery do not routinely undergo
the same immunohistologic staining that would be performed for permanent pathology
analysis. Immunostaining was originally demonstrated on paraffin-embedded sections,
and the application to frozen sections is anecdotal and unproven.2 One such
immunohistologic marker is CD 34, which is useful in differentiating DFSP from other
fibrohistiocytic tumors.25 This stain has been incorporated into the final stages of Mohs
surgery at some institutions in order to confirm free margins.10 Alternatively, authors
have suggested preparing paraffin sections as a final layer for analysis after negative
margins are found on MMS, which would allow for immunohistologic processing.26
Despite these concerns, the pathologic techniques used in Mohs surgery have been
shown to provide an excellent cure rate. Although data is limited compared to surgical
excision, very few recurrences have been reported. In one of the largest trails to date,
Ratner et al. reviewed the records of 50 patients with DFSP treated with Mohs surgery.
With an average follow up time of 4.8 years, the authors observed only one patient who
developed a local recurrence.13 Wacker et. al performed a literature review pooling 303
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patients treated with Mohs surgery for DFSP. In this group, only six patients developed
recurrent disease, resulting in a 2% recurrence rate.26 Lower rates have been observed
using modified Mohs surgery techniques, such as that proposed by Breuninger and
Schaumburg-Lever, where paraffin-embedded sections are employed as well as
immunohistochemistry for CD34.27,28
Exclusion criteria for treatment of DFSP with Mohs surgery varies by the
institution and resources available (Table 3.) Tumors that are large, recurrent, previously
irradiated, or aggressive are more likely to be found to be unresectable by Mohs surgery,
however these same risk factors may also be indications for Mohs surgery.29 Recurrent
lesions provide additional challenges to Mohs surgeons because of tissue distortion and
scarring. In very large lesions, there is an increased risk of extension of the tumor
beyond the subcutis into vital structures such as bone, where paraffin sections may be
necessary for accurate pathology. As Mohs surgery is usually performed under local
anesthesia, larger lesions may limit the use of Mohs surgery when lidocaine toxicity is a
concern. For lesions with these characteristics, surgical excision may be the treatment of
choice.

Table 3. Exclusion Criteria for Mohs Surgery
Patient preference
Needle phobia
Large lesions (criteria dependent on the institution)
Lesion exceeds limits of local anesthesia
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Mohs surgery may play a role in subsequent stages of tumor resection for lesions that
were initially not amenable to Mohs surgery. As mentioned in our results, one patient
with recurrent DFSP of the forehead was initially treated with surgical resection. She
was referred for Mohs surgery when permanent pathology showed a foci of tumor cells
extending into the upper eyelid. Mohs surgery permitted mapping of the remaining
tumor and removal with minimal tissue loss.
Occasionally Mohs surgery is terminated intraoperatively when the margins are still
known to be positive if the lesion extends into deep structures that may not be further
removed under local anesthesia.28 In our study three patients continued to exhibit
positive margins after four stages of Mohs surgery. All of the patients presented with
DFSP in a functionally or cosmetically important region - the anterior scalp along the
hairline border, the clavicle, and the anterior foot with tumor extension into the anterior
tendons. Due to the size of the defects (7.2 by 5.7 cm, 6.5 by 5.5cm, and 5 by 5 cm,
respectively) a second stage procedure under general anesthesia was planned for
reconstruction, and further surgical resection was performed at that time. Although full
resection was not possible with Mohs surgery, initial resection with Mohs surgery served
to the isolate the extension of tumor cells, and allowed for more focused surgical
resection in areas where tissue conservation was critical.

Surgical Excision with Delayed Closure

Mohs-trained surgeons and specialized Mohs teams are less available than
traditional surgical teams, and thus expense and resources may limit when Mohs surgery
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can be performed. When Mohs surgery is not feasible because of logistical concerns or
tumor characteristics, surgical re-excision of tumor positive areas until tumor-free
margins are obtained has been found to ensure a high cure rate.7 Delayed closure has
been advocated by several authors as a method of ensuring complete tumor extirpation
before reconstruction.29,30 Sondak et al. describe a staged approach to surgery where the
wound is covered with allograft with planned re-operation seven days later if primary
closure without undermining is not possible. Using this approach, the authors found no
recurrences among 45 patients.29
Full tumor resection with delayed closure has a high rate of cure even among these
patients who are most at risk for recurrence. Thiele et al. analyzed the long term
outcomes of seven patients who presented to their institution with recurrent DFSP of the
head and neck.31 Patients in the analysis were included only if at least one attempt to
surgically cure the patient had been performed previously at a different institution, and
patients had on average undergone surgery three times previously. One patient included
in the study had undergone 12 operations for recurrent DFSP of the infraorbital region.
As discussed earlier, recurrent lesions have been found to be significantly larger with a
higher propensity for bone involvement, future recurrence, and metastasis.8 In addition,
DFSP of the head and neck have a notoriously high rate of recurrence, ranging between
50 and 80%.2,31 These patients, therefore, represent a group that is extremely at risk for
recurrence and disease progression. All patients in the study by Thiele et al. were treated
with surgical excision of the tumor with a minimum 1 cm free surgical margin, followed
by coverage with artificial skin until definite histopathologic examination confirmed free
surgical margins. Six out of seven patients required at least two operations in order to
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achieve complete free margins. After this treatment method, at five years the patient
survival rate was 100%, and only one patient had experienced recurrence. This study
shows that staged surgical resection with delayed closure can minimize recurrence rates
even in the most challenging of cases.
In the interim between staged excisions, allograft is usually used as a temporary
dressing. However, it is likely that other methods of temporary dressing may be equally
if not more successful. Pearson and Amsberry reported their experience using a negative
pressure wound dressing (Wound-Vac®) as a temporary dressing while waiting for final
permanent pathology results after wide excision of a DFSP.4 The authors found that the
negative pressure wound dressing decreased wound care and dressing changes as
compared to traditional dressings, and provided an optimal wound bed for definitive
wound management.

Reconstruction

Due to the infiltrating nature of DFSP, tumor resection often results in large
defects that require extensive undermining or reconstruction. In a retrospective study of
218 patients treated for DFSP, Fiore et al. found that one-third of patients required
reconstructive surgery, and the need for reconstruction was more frequent in patients with
tumors of the head and neck.6 The NCCN guidelines promote the use of a STSG to
monitor for recurrence when positive margins may be in question or when the clinician
deems this appropriate. Historically, STSG have been used in closure for DFSP under
the auspices that they would allow for better monitoring of local recurrence. For years
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surgeons employed STSG to obtain closure after melanoma resection. This was done out
of a concern that flap repair would camouflage early local recurrences in the bed of
excision, and possibly increase the risk for local recurrence as a result of additional
dissection. 31 However, it has not been shown that skin grafts increase the sensitivity of
monitoring for recurrence. In addition, STSG provide poor aesthetic outcomes, with
problems such as color mismatch, contour deformity, wound contracture, and
disfigurement. 32 Cassileth et. al. surveyed 176 patients who had undergone Melanoma
resection followed by grafted closure. The authors found that the deep scar depression
from skin grafting led to increased psychological distress among patients following
surgery. 33 Just as for melanoma, there is little evidence that STSG allows for improved
surveillance of DFSP recurrence. Flap coverage has been shown to be safe, and provides
significant advantages such as a superior cosmetic results, earlier post-operative
ambulation and and faster mobilization when compared to skin grafts, resulting in a
decreased length of hospital stay. 31,33 Given that complete removal of tumor cells is
considered curative for DFSP2 we believe that flap closure should be employed when
possible after negative margins are demonstrated by permanent pathology.

Adjuvant Chemotherapy

Although fewer than 5% of patients with DFSP develop metastatic sarcoma, the
prognosis of such patients is poor, with survival ranging from one to 48 months. 2,20,34,35
Metastasis predominantly occur through a hematogenous route to the lungs, but have also
been reported in the brain, bone, and peritracheal area.2 Chemotherapy that has
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traditionally be used to treat sarcomas has not been found to be effective in treating
DFSP. 7 Imatinib mesylate, (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is a
tyrosine kinase inhibitor that has proven clinical activity against chronic myelogenous
leukemia expressing bcr-abl and gastrointestinal stromal tumors expressing c-kit. 35,36 As
mentioned earlier, the pathology of DFSP is thought to result from a translocation
resulting in production of a fusion protein that causing continuous stimulation of platelet
PDGF protein tyrosine kinase, resulting in increased production of PDGF and abnormal
cellular proliferation.7 (Figure 4) Imatinib, which selectively inhibits PDGF alpha and
beta receptors, has demonstrated activity against DFSP cells in vitro and vivo. 20 Due to
this inhibition, imatinib has the potential to serve as a targeted treatment modality for
DFSP.
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Figure 4. The pathology of Dermatofibrosarcoma protuberans results from the
chromosomal translocation t(17;22) resulting in fusion of the COL1A1 and PDGFB
genes. Protein product from this fusion causes continuous activation of the PDGFB
receptor and oncogenic intracellular signaling. Imatinib inhibits PDFGR protein-tyrosine
kinase. From McArthur G. Molecularly targeted treatment for dermatofibrosarcoma
protuberans. Semin Oncol 2004 ; 31 (2 Suppl 6):30-6. Reprinted with permission from
Elsevier. 20
Labropoulos and Fletcher reported one of the first successes of imatinib therapy in
the treatment of DFSP in 2005.37 They described a 48 year-old woman with recurrent
DFSP of the upper back. At the time of the third recurrence, she was found to have the
fibrosarcomatous DFSP variant with metastasis to one lymph node in her axilla. A
staging chest computed tomography scan showed three nodular lesions in the bilateral
lungs, the largest measuring 8mm. The patient was initially treated with a combination
chemotherapy regimen protocol that was traditionally used for high-grade soft tissue
sarcoma, which consisted of three cycles of ifosphamide with MESNA and liposomal
doxorubicin, but was unresponsive to the regiment. She was begun on imatinib mesylate
therapy, and within one month there was a dramatic decrease in tumor size on the
patient's back, and a CT of the chest showed resolution of the three lung nodules. The
patient experienced minimal toxicity from imatinib and complete remission of the
metastatic DFSP was observed at 20 months follow up. This is one of seven published
case reports showing successful treatment of metastatic DFSP with imatinib.
The largest trial in the literature thus far - the Imatinib Target Exploration
Consortium Study B2225 - shows promising results for 10 patients treated with
imatinib.38 Eight of the patients were treated for locally advanced disease and two were
treated for metastatic disease. Half of the patients with locally advanced disease
experienced complete disappearance of measurable and assessable disease. The other
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half experienced a decrease of at least 50% in tumor diameter, which permitted full
surgical resection of the tumor. Of the two patients with metastatic disease, one
experienced a partial response that lasted seven months. The other patient experienced
no change in tumor size and died on day 32 of the trial. This was the only patient in the
study found to lack the t(17;22) abnormality. It seems that patients may have differential
sensitivity to therapy, perhaps based on tumor expression of t(17;22.)38,20
Imatinib is currently approved for treatment of adult patients with unresectable,
recurrent, and/or metastatic DFSP who are not eligible for surgery. It is possible that the
role of imatinib may be expanded to include preoperative debulking of large tumors
located in areas of cosmetic and functional importance. Mehrany et al. published a recent
case report describing the use of imatinib as a neoadjuvant chemotherapeutic agent for
tumor shrinkage in the case of unresectable DFSP. The authors followed a 46 year-old
patient with a large DFSP of the left cheek who underwent therapy with imatinib before
surgical resection of the lesion.35 At the time of diagnosis, computed tomography and
magnetic resonance imaging scans showed the tumor abutting and possibly invading
muscles of facial expression. After initiation of therapy, the patient experienced a
dramatic decrease in tumor size with concurrent softening of the tumor. By the 20th
month of therapy, the tumor was small enough to be fully resected by Mohs surgery.
Because of the decrease in tumor size, the patient maintained nearly full function of the
muscles of facial expression. At eighteen months he has had no disease recurrence.
However, some pathologists have expressed concern that treatment with imatinib
mesylate could complicate pathologic interpretation of lesions. In a letter to the editor,
Ortiz et al. postulated that imatinib could create noncontinuous islands of tumor, giving
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the false impression of clear margins after Mohs surgery.39 Because of this risk, the
authors proposed that imatinib be used as in the postoperative period rather than as a
neoadjuvant therapy.39 While larger, case controlled trials are needed to further
understand the risks of imatinib, it is clear that this chemotherapeutic shows enormous
potential for certain subgroups of patients with DFSP.

Radiation Therapy

Several authors have suggested a role for radiation therapy as an adjuvant to
surgery in the treatment of DFSP for lesions with close or positive margins.18,40 Ballo et
al. reviewed 19 patients at the University of Texas M. D. Anderson Cancer Center who
received radiation therapy with doses of 50-60 Gy for DFSP.40 Ten of the patients
presented with recurrent disease. Seventeen patients received postoperative radiation
therapy, six with positive microscopic margins following surgery and 10 with negative
microscopic margins and a surgical margin of less than 3 cm. The two patients that
received preoperative radiation therapy achieved complete surgical resection. Only one
patient developed recurrence during the median study follow-up of six years. This
patient’s course was complicated by prolonged wound healing which delayed radiation
therapy, and regrowth of the disease before treatment was started.
A later study by Suit et al. at the Massachusetts General Hospital assessed the
results of radiation therapy as a primary treatment for lesions not amenable to surgery.41
Although the number of patients was small (n=3), local control was achieved and patients
had no evidence of disease at 106, 85, and 108 months. These patients presented with
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moderately sized tumors ranging from 3 by 5cm to 8.5 by 4.5 cm, on the upper anterior
chest wall, the scalp behind the hairline, and the chin. In addition, all patients had
excellent cosmetic results with the exception of atrophy and telangectasia in one
patient.41
While promising, the data for radiation therapy is limited, and therapy may not be
without risks. There are reports that radiation may induce new or high-grade tumors.42
The National Comprehensive Cancer Network suggests consideration of radiation
therapy for metastatic lesions or in cases of recurrent disease where unacceptable
functional or cosmetic outcomes will occur.
In conclusion, we believe that the management of DFSP should be focused on
establishment of negative pathology before reconstruction. Given our experience, we
present a novel algorithm that minimizes the risk of residual microscopic disease. In
addition to decreasing local and distant DFSP recurrence, we believe this algorithm will
provide optimal aesthetic results for patients.
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